erythrosine has been researched along with zd 6474 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bénard, J; Bidart, JM; Farinotti, R; Forestier, F; Gil, S; Jovelet, C | 1 |
1 other study(ies) available for erythrosine and zd 6474
| Article | Year |
|---|---|
Inhibition of P-glycoprotein functionality by vandetanib may reverse cancer cell resistance to doxorubicin.
Topics: Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Female; Fluoresceins; Fluorescent Dyes; Humans; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Ovarian Neoplasms; Phenotype; Piperidines; Protein Kinase Inhibitors; Quinazolines; Rhodamine 123; Time Factors | 2012 |